David Abernethy
Overview
Explore the profile of David Abernethy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abernethy D, Bennie J, Pavey T
PLoS One
. 2025 Jan;
20(1):e0316051.
PMID: 39774437
Background: Physical inactivity is a significant public health concern associated with numerous adverse health outcomes and substantial economic costs. This study describes the prevalence, trends and correlates for adherence to...
2.
Butzkueven H, Ponsonby A, Stein M, Lucas R, Mason D, Broadley S, et al.
Brain
. 2023 Dec;
147(4):1206-1215.
PMID: 38085047
Low serum levels of 25-hydroxyvitamin D [25(OH)D] and low sunlight exposure are known risk factors for the development of multiple sclerosis. Add-on vitamin D supplementation trials in established multiple sclerosis...
3.
4.
La Flamme A, Abernethy D, Sim D, Goode L, Lockhart M, Bourke D, et al.
BMJ Neurol Open
. 2021 Mar;
2(1):e000060.
PMID: 33681788
Objective: Because clozapine and risperidone have been shown to reduce neuroinflammation in humans and mice, the Clozapine and Risperidone in Progressive Multiple Sclerosis (CRISP) trial was conducted to determine whether...
5.
Horsham C, Antrobus J, Olsen C, Ford H, Abernethy D, Hacker E
JMIR Mhealth Uhealth
. 2020 Sep;
8(9):e21243.
PMID: 32936083
Background: Australia and New Zealand have the highest skin cancer incidence rates worldwide, and sun exposure is the main risk factor for developing skin cancer. Sun exposure during childhood and...
6.
Khalilidehkordi E, Clarke L, Arnett S, Bukhari W, Sanchez S, OGorman C, et al.
Front Neurol
. 2020 Jul;
11:537.
PMID: 32612571
Neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) show overlap in their clinical features. We performed an analysis of relapses with the aim of determining differences between the two...
7.
Bukhari W, Clarke L, OGorman C, Khalilidehkordi E, Arnett S, Prain K, et al.
J Neurol
. 2020 Feb;
267(5):1431-1443.
PMID: 32006158
Neuromyelitis optica spectrum disorders (NMOSD) are an inflammation of the central nervous system associated with autoantibodies to aquaporin-4. We have undertaken a clinic-based survey of NMOSD in the Australia and...
8.
Watson E, Rosemergy I, Taylor J, Abernethy D, Lanford J
Neurol Clin Pract
. 2018 Mar;
5(6):536-537.
PMID: 29595829
No abstract available.
9.
Bukhari W, Prain K, Waters P, Woodhall M, OGorman C, Clarke L, et al.
J Neurol Neurosurg Psychiatry
. 2017 May;
88(8):632-638.
PMID: 28550069
Objectives: We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of...
10.
Chuluundorj D, Harding S, Abernethy D, La Flamme A
Immunol Cell Biol
. 2016 Oct;
95(3):297-305.
PMID: 27694998
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system, and monocytes contribute to MS-associated neuroinflammation. While classically activated monocytes promote inflammation, type II-activated monocytes improve the course...